Australian biotech market today 14.04.09
Tuesday, 14 April, 2009
The overall healthcare index was up on today’s trading at 2.30pm, following the trend of the rest of the indices. The All Ordinaries is up 2.5 per cent.
Cellestis (ASX:CST) is up 19c to $2.55 on the news that its TB diagnostic QuantiFERON-TB Gold In-Tube has received regulatory approval in Japan.
ChemGenex (ASX:CXS) is continuing to enjoy gains after announcing it had raised $10 million in secondary financing last week, up 4c to 46c.
Acrux (ASX:ACR) is up 2c to 65c, as is Biota (ASX:BTA) to 66c. Mesoblast (ASX:MSB) is up 5c to 85c.
Cochlear (ASX:COH) is up 68c, CSL (ASX:CSL) is down 11c and ResMed (ASX:RMD) is up 4c.
Pharmaxis (ASX:PXS) is down a steep 13c to $2.02 on reasonable volumes, as is Novogen (ASX:NRT), down 13.5 per cent to 48c. QRxPharma (ASX:QRX) is up 4c to 32c.
Progen (ASX:PGL) is up 3.8 per cent to 95c while Probiotec (ASX:PBP) is again enjoying healthy rises, up 6.2 per cent to $1.89.
Living Cell Technologies (ASX:LCT) is down 3.5c to 12c, while there has been some rare movement with LabTech Systems (ASX:LBT), up a cent to 14.5.
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
